MCID: PDT021
MIFTS: 35

Pediatric Osteosarcoma

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Pediatric Osteosarcoma

MalaCards integrated aliases for Pediatric Osteosarcoma:

Name: Pediatric Osteosarcoma 12 15
Childhood Osteosarcoma 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3361
NCIt 51 C6585
UMLS 74 C1332986

Summaries for Pediatric Osteosarcoma

MalaCards based summary : Pediatric Osteosarcoma, also known as childhood osteosarcoma, is related to osteogenic sarcoma and methotrexate toxicity or dose selection. An important gene associated with Pediatric Osteosarcoma is SLC19A1 (Solute Carrier Family 19 Member 1), and among its related pathways/superpathways are Metabolism and Metabolism of water-soluble vitamins and cofactors. The drugs Cisplatin and nivolumab have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are growth/size/body region and integument

Related Diseases for Pediatric Osteosarcoma

Graphical network of the top 20 diseases related to Pediatric Osteosarcoma:



Diseases related to Pediatric Osteosarcoma

Symptoms & Phenotypes for Pediatric Osteosarcoma

MGI Mouse Phenotypes related to Pediatric Osteosarcoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.73 DHFR HK2 MTHFR ROCK1 SLC19A1 SOX4
2 integument MP:0010771 9.55 DHFR MTHFR ROCK1 SLC19A1 SOX4
3 liver/biliary system MP:0005370 9.26 DHFR MTHFR SHMT1 SLC19A1
4 mortality/aging MP:0010768 9.17 DHFR HK2 MTHFR ROCK1 SHMT1 SLC19A1

Drugs & Therapeutics for Pediatric Osteosarcoma

Drugs for Pediatric Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2,Not Applicable 15663-27-1 2767 441203 84093
2
nivolumab Approved Phase 1, Phase 2 946414-94-4
3
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
4 Pharmaceutical Solutions Phase 2
5 Antimetabolites Phase 1, Phase 2,Not Applicable
6 Antimetabolites, Antineoplastic Phase 1, Phase 2,Not Applicable
7 Antineoplastic Agents, Immunological Phase 1, Phase 2
8
leucovorin Approved Not Applicable 58-05-9 143 6006
9
Ifosfamide Approved Not Applicable 3778-73-2 3690
10
Carboplatin Approved Not Applicable 41575-94-4 10339178 38904 498142
11
Mechlorethamine Approved, Investigational Not Applicable 51-75-2 4033
12
Methotrexate Approved Not Applicable 1959-05-2, 59-05-2 126941
13
Doxorubicin Approved, Investigational Not Applicable 23214-92-8 31703
14
Mesna Approved, Investigational Not Applicable 3375-50-6 598
15
Gemcitabine Approved Not Applicable 95058-81-4 60750
16
Sargramostim Approved, Investigational Not Applicable 123774-72-1, 83869-56-1
17
Folic Acid Approved, Nutraceutical, Vet_approved Not Applicable 59-30-3 6037
18
Doxil Approved June 1999 Not Applicable 31703
19 Protective Agents Not Applicable
20 Antimitotic Agents Not Applicable
21 razoxane Not Applicable
22 Folate Not Applicable
23 Antirheumatic Agents Not Applicable
24 Vitamin B9 Not Applicable
25 Antineoplastic Agents, Alkylating Not Applicable
26 Immunosuppressive Agents Not Applicable
27 Dermatologic Agents Not Applicable
28 Cardiotonic Agents Not Applicable
29 Immunologic Factors Not Applicable
30 Anti-Bacterial Agents Not Applicable
31 Vitamin B Complex Not Applicable
32 Anti-Infective Agents Not Applicable
33 Antiviral Agents Not Applicable
34 Folic Acid Antagonists Not Applicable
35
Isophosphamide mustard Not Applicable 0
36 Nucleic Acid Synthesis Inhibitors Not Applicable
37 Alkylating Agents Not Applicable
38 Antibiotics, Antitubercular Not Applicable
39 Topoisomerase Inhibitors Not Applicable

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors Recruiting NCT02581384 Phase 1, Phase 2
2 Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma Active, not recruiting NCT01650090 Phase 2 Inhaled Lipid Cisplatin (ILC)
3 Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma Not yet recruiting NCT03628209 Phase 1, Phase 2 Nivolumab;Azacitidine
4 Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity Recruiting NCT03139318 Not Applicable
5 The Impact of Cancer on the Physical and Psychosocial Well-being Among Childhood Osteosarcoma Survivors Recruiting NCT03298971
6 Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy Terminated NCT00673179 Not Applicable Doxorubicin;Cisplatin;Methotrexate;Leucovorin;Dexrazoxane;Ifosfamide;Gemcitabine;Sargramostim;Mesna

Search NIH Clinical Center for Pediatric Osteosarcoma

Genetic Tests for Pediatric Osteosarcoma

Anatomical Context for Pediatric Osteosarcoma

MalaCards organs/tissues related to Pediatric Osteosarcoma:

42
Bone

Publications for Pediatric Osteosarcoma

Articles related to Pediatric Osteosarcoma:

(show top 50) (show all 115)
# Title Authors Year
1
Clinical Prognostic Factors and Outcome in Pediatric Osteosarcoma: Effect of Delay in Local Control and Degree of Necrosis in a Multidisciplinary Setting in Lebanon. ( 30946633 )
2019
2
Curative-intent radiotherapy for pediatric osteosarcoma: The St. Jude experience. ( 31012273 )
2019
3
Downregulated Adhesion-Associated microRNAs as Prognostic Predictors in Childhood Osteosarcoma. ( 28944406 )
2019
4
Educational Case: Pediatric Osteosarcoma. ( 30859126 )
2019
5
Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt. ( 30629005 )
2019
6
Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. ( 28806574 )
2018
7
Growth of epiphysis after epiphyseal-preservation surgery for childhood osteosarcoma around the knee joint. ( 29875014 )
2018
8
The Efficiency and Toxicity of Mifamurtide in Childhood Osteosarcoma. ( 29889801 )
2018
9
Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity. ( 30454696 )
2018
10
Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk. ( 30038050 )
2018
11
The Effect of Clown Intervention on Self-Report and Biomarker Measures of Stress and Fatigue in Pediatric Osteosarcoma Inpatients: A Pilot Study. ( 29900751 )
2018
12
Carbon ion radiotherapy for inoperable pediatric osteosarcoma. ( 29796166 )
2018
13
miR‑188 suppresses tumor progression by targeting SOX4 in pediatric osteosarcoma. ( 29749512 )
2018
14
Biological function of microRNA-30c/SOX9 in pediatric osteosarcoma cell growth and metastasis. ( 29364496 )
2018
15
Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. ( 29357275 )
2018
16
Childhood osteosarcoma: Incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000-2013. ( 28409896 )
2017
17
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report. ( 29390436 )
2017
18
TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma. ( 29163677 )
2017
19
Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina. ( 28937522 )
2017
20
The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients. ( 28592186 )
2017
21
Pediatric Osteosarcoma: An Updated Review. ( 28469335 )
2017
22
Immunotherapeutic approaches in pediatric osteosarcoma. ( 28353326 )
2017
23
The expression and function of miRNA-106 in pediatric osteosarcoma. ( 28272712 )
2017
24
ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma. ( 28267080 )
2017
25
Novel insights and therapeutic interventions for pediatric osteosarcoma. ( 27651036 )
2017
26
Multimodality Imaging in Pediatric Osteosarcoma in the Era of Image Gently and Image Wisely Campaign With a Close Look at the CT Scan Radiation Dose. ( 26583624 )
2016
27
The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. ( 26603261 )
2016
28
CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells. ( 26715273 )
2016
29
Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density. ( 27104175 )
2016
30
Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma. ( 26583357 )
2016
31
Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma. ( 27261617 )
2016
32
Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. ( 27104192 )
2016
33
Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival. ( 25323470 )
2015
34
PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma. ( 26116768 )
2015
35
Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma. ( 26512351 )
2015
36
Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. ( 24038809 )
2014
37
Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. ( 24123836 )
2014
38
Combined microRNA-340 and ROCK1 mRNA profiling predicts tumor progression and prognosis in pediatric osteosarcoma. ( 24398981 )
2014
39
Management of local recurrence of pediatric osteosarcoma following limb-sparing surgery. ( 24558066 )
2014
40
Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( 24667129 )
2014
41
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. ( 24703847 )
2014
42
Pediatric osteosarcoma: a single institution's experience. ( 25365431 )
2014
43
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( 25520112 )
2014
44
In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma. ( 25594070 )
2014
45
Phyllodes tumor in survivors of childhood osteosarcoma: a single institution's experience. ( 24065044 )
2014
46
Successful management of a childhood osteosarcoma with epiphysiolysis and distraction osteogenesis. ( 25089114 )
2014
47
Long-term pulmonary function after metastasectomy for childhood osteosarcoma: a report from the St Jude lifetime cohort study. ( 24795268 )
2014
48
Pathological fracture as the presenting feature in pediatric osteosarcoma. ( 23281226 )
2013
49
Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. ( 23430441 )
2013
50
Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( 23621194 )
2013

Variations for Pediatric Osteosarcoma

Expression for Pediatric Osteosarcoma

Search GEO for disease gene expression data for Pediatric Osteosarcoma.

Pathways for Pediatric Osteosarcoma

Pathways related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.53 ATIC DHFR HK2 MTHFR SHMT1 SLC19A1
2
Show member pathways
12.16 DHFR MTHFR SHMT1 SLC19A1
3 12.03 HK2 MTHFR SHMT1
4
Show member pathways
11.82 HK2 MTHFR SHMT1
5
Show member pathways
11.79 DHFR MTHFR SHMT1 SLC19A1
6
Show member pathways
11.41 ATIC DHFR MTHFR SHMT1
7 10.51 ATIC DHFR MTHFR SHMT1 SLC19A1

GO Terms for Pediatric Osteosarcoma

Biological processes related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metabolic process GO:0008152 9.58 ATIC HK2 MTHFR
2 cellular response to leukemia inhibitory factor GO:1990830 9.46 HK2 SHMT1
3 negative regulation of translation GO:0017148 9.43 DHFR SHMT1
4 tetrahydrofolate interconversion GO:0035999 9.37 MTHFR SHMT1
5 one-carbon metabolic process GO:0006730 9.33 DHFR MTHFR SHMT1
6 tetrahydrofolate biosynthetic process GO:0046654 9.32 ATIC DHFR
7 dihydrofolate metabolic process GO:0046452 9.26 ATIC DHFR
8 tetrahydrofolate metabolic process GO:0046653 9.13 DHFR MTHFR SHMT1
9 folic acid metabolic process GO:0046655 8.92 DHFR MTHFR SHMT1 SLC19A1

Molecular functions related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP binding GO:0050661 9.26 DHFR MTHFR
2 translation repressor activity, mRNA regulatory element binding GO:0000900 9.16 DHFR SHMT1
3 folic acid binding GO:0005542 8.96 DHFR SLC19A1
4 catalytic activity GO:0003824 8.92 ATIC HK2 MTHFR SHMT1

Sources for Pediatric Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....